https://www.businesswire.com/news/h...Pipeline-with-New-Autoimmune-Candidate-CDR111
CDR111, CDR-Life’s newest clinical candidate, is a trispecific molecule targeting CD19, BCMA and CD3, designed to achieve immune reset through broad B cell depletion. This novel therapeutic approach represents a significant expansion of the company's product portfolio beyond oncology into autoimmune diseases, with potential applications across multiple autoimmune conditions.
CDR111, CDR-Life’s newest clinical candidate, is a trispecific molecule targeting CD19, BCMA and CD3, designed to achieve immune reset through broad B cell depletion. This novel therapeutic approach represents a significant expansion of the company's product portfolio beyond oncology into autoimmune diseases, with potential applications across multiple autoimmune conditions.